Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
KRYS Krystal Biotech Inc
- Stocks
- Healthcare
- NASDAQ: KRYS
Price (delayed)
$130.6
Market cap
$3.77B
P/E Ratio
30.23
Dividend/share
N/A
EPS
$4.32
Enterprise value
$3.48B
Krystal Biotech, Inc. is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases.
Highlights
The EPS has soared by 118% YoY and by 38% from the previous quarter
The net income has soared by 117% YoY and by 39% from the previous quarter
The company's quick ratio rose by 31% QoQ but it fell by 26% YoY
The debt has grown by 33% from the previous quarter and by 22% YoY
Key stats
What are the main financial stats of KRYS
Market
Valuations
Earnings
Shares outstanding
28.9M
Market cap
$3.77B
Enterprise value
$3.48B
Price to earnings (P/E)
30.23
Price to book (P/B)
3.82
Price to sales (P/S)
11.29
EV/EBIT
25.18
EV/EBITDA
24.01
EV/Sales
10.42
Revenue
$333.45M
Gross profit
$310.78M
Operating income
$108.56M
Net income
$123.96M
EBIT
$138.02M
EBITDA
$144.76M
Free cash flow
$129.75M
Per share
Balance sheet
Liquidity
EPS
$4.32
EPS diluted
$4.17
Free cash flow per share
$4.5
Book value per share
$34.18
Revenue per share
$11.57
TBVPS
$37.29
Total assets
$1.07B
Total liabilities
$89.74M
Debt
$9.66M
Equity
$984.67M
Working capital
$687.31M
Debt to equity
0.01
Current ratio
9.65
Quick ratio
9.06
Net debt/EBITDA
-2.07
Margins
Efficiency
Dividend
EBITDA margin
43.4%
Gross margin
93.2%
Net margin
37.2%
Operating margin
32.6%
Return on assets
12.3%
Return on equity
13.6%
Return on invested capital
23.5%
Return on capital employed
13.9%
Return on sales
41.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KRYS stock price
How has the Krystal Biotech stock price performed over time
Intraday
0.21%
1 week
-1.2%
1 month
-20.7%
1 year
-20.26%
YTD
-16.63%
QTD
-27.57%
Financial performance
How have Krystal Biotech's revenue and profit performed over time
Revenue
$333.45M
Gross profit
$310.78M
Operating income
$108.56M
Net income
$123.96M
Gross margin
93.2%
Net margin
37.2%
The operating margin has soared by 146% YoY and by 44% from the previous quarter
The net income has soared by 117% YoY and by 39% from the previous quarter
The operating income has soared by 65% from the previous quarter
The net margin has contracted by 38% YoY but it has grown by 21% from the previous quarter
Price vs fundamentals
How does KRYS's price correlate with its fundamentals
Growth
What is Krystal Biotech's growth rate over time
Valuation
What is Krystal Biotech stock price valuation
P/E
30.23
P/B
3.82
P/S
11.29
EV/EBIT
25.18
EV/EBITDA
24.01
EV/Sales
10.42
The EPS has soared by 118% YoY and by 38% from the previous quarter
KRYS's price to earnings (P/E) is 50% lower than its last 4 quarters average of 59.9
KRYS's P/B is 31% below its last 4 quarters average of 5.5 and 7% below its 5-year quarterly average of 4.1
Krystal Biotech's equity has increased by 23% YoY and by 4% QoQ
The P/S is 46% below the last 4 quarters average of 21.1
The revenue has grown by 15% since the previous quarter
Efficiency
How efficient is Krystal Biotech business performance
The ROE has soared by 77% YoY and by 32% from the previous quarter
Krystal Biotech's ROA has soared by 68% YoY and by 31% from the previous quarter
Krystal Biotech's return on invested capital has surged by 67% YoY and by 30% QoQ
The ROS has contracted by 33% YoY but it has grown by 26% from the previous quarter
Dividends
What is KRYS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KRYS.
Financial health
How did Krystal Biotech financials performed over time
The total liabilities has soared by 66% YoY but it has contracted by 18% from the previous quarter
The current ratio is up by 33% since the previous quarter but it has declined by 24% year-on-year
The debt is 99% less than the equity
The debt has grown by 33% from the previous quarter and by 22% YoY
Krystal Biotech's equity has increased by 23% YoY and by 4% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.